Source comparison
CJC-1295 Ipamorelin Gold Standard GH Stack: Research Compound Comparison
CJC-1295 (with DAC) GHRH receptor agonist with albumin binding GHRH receptors on anterior pituitary 6–8 days 1–2 mg twice weekly None. Selective for GH pathway Gold standard for sustained GH synthesis; DAC modification eliminates need for daily dosing Ipamorel
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- GHRH receptor agonist with albumin binding
- GHRH receptors on anterior pituitary
- 6–8 days
- 1–2 mg twice weekly
- None. Selective for GH pathway
- Gold standard for sustained GH synthesis; DAC modification eliminates need for daily dosing
- Ipamorelin
- Selective ghrelin receptor agonist
- GHS-R1a (ghrelin receptors)
- 2 hours
- 200–300 mcg daily or twice daily
- None. Highly selective, no cortisol elevation
- Preferred GH secretagogue for pulsatile release without side-effect profile of earlier GHRPs
- GHRP-2
- Non-selective GH secretagogue
- GHS-R1a + additional receptor subtypes
- 20–30 minutes
- 100–300 mcg 2–3× daily
- Moderate cortisol and prolactin elevation
- Effective but non-selective; cortisol spikes limit long-term use in sensitive research models
- Hexarelin
- Potent but non-selective GHS
- GHS-R1a + CD36 scavenger receptors
- 70 minutes
- 100–200 mcg 2× daily
- Strong cortisol/prolactin response + cardiac effects
- Most potent single-dose GH release but tachyphylaxis develops within 4–6 weeks; not suitable for extended protocols
- MK-677 (Ibutamoren)
- Orally active ghrelin mimetic
- GHS-R1a
- 24 hours
- 10–25 mg daily (oral)
- Minimal cortisol impact; increases appetite significantly
- Convenient oral administration but less precise control over GH pulses compared to injectable peptides